Hot News

中生制藥:附屬涉行賄屬個人行為今復牌 @ 2013-09-13T09: Back Hot News
Keyword:中生制藥 賄賂 中國 天晴 醫生
Concept:公司正大天晴 , 賄賂中國生物制藥
核心提示:總部設在香港的中國生物制藥股份有限公司(下稱「中生制藥」),旗下最大子公司江蘇「正大天晴藥業」,日前被央視揭露涉嫌商業賄賂,導致中生制藥(1177)昨日股價一度下跌25%,其香港上市股票在午盤前停牌,收市趺16%。正大天晴藥業昨日回應事件稱,涉案的相關人員事後已被停職候查。
內地打貪腐戰線不斷擴大,醫藥業成為最新目標。繼7月葛蘭素史克藥廠賄賂案後,中央電視台踢爆中國生物制藥(1177)旗下的江蘇正大天晴藥廠,亦款待醫生到泰國旅游以推銷藥物,涉嫌商業賄賂。受消息拖累,中生制藥昨天股價一度急瀉近25%,至中午收市前集團突然宣布停牌,稱等待澄清有關報道。
德銀引述中國生物制藥(01177.HK)管理層表示,由於涉及央視營銷活動(有知情人士在節目上提及中生制藥持股60%江蘇正大天晴,擬邀醫生出游或構成違法),預計事件可能影響集團下半年盈利增長2%-3%。此外,德銀又認為,中央反賄賂短期對藥品推廣活動影響的沖擊將較預期大,且可能持續至明年。此外,瑞信也下調中生制藥評級至「跑輸大市」目標價降至4.2元。

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.